Hypoxia inducing factor 1 alpha-transfected cardiac stem cells in repair of necrotic myocardium

doi:10.3969/j.issn.2095-4344.2015.23.024

Abstract

Abstract:

BACKGROUND: Cardiac stem cells transplanted to the myocardial infarction area can effectively improve ventricular remodeling and promote heart function. But the survival rate of transplanted cells is lower in the infracted area under hypoxic microenvironment. Hypoxia inducing factor 1 alpha under anoxic conditions can stably express, and meanwhile increase the activity and survival ability of myocardial cells.
OBJECTIVE: To elaborate the research progress in hypoxia inducing factor 1 alpha-transfected cardiac stem cells for treatment of myocardial infarction from the following aspects: cardiac stem cell characteristics, mechanism underlying myocardial protection of hypoxia inducing factor 1 alpha, selection of carriers and transplantation approach.
METHODS: A computer-based search of CNKI and PubMed was performed for articles related to cardiac stem cells and hypoxia inducing factor 1 alpha published from January 2000 to January 2015. The keywords were “cardiac stem cells, hypoxia inducible factor 1(HIF-1a), gene delivery” in Chinese and English, respectively, which appeared in the title and abstract. Finally, 37 relevant articles were enrolled in result analysis.
RESULTS AND CONCLUSION: Several studies have confirmed that hypoxia inducing factor 1 alpha can improve the survival rate of cardiac stem cells under anoxic conditions. Increasing evidences from animal experiments have shown that cardiac stem cells and hypoxia inducing factor 1 alpha exert protective and repairing effects on myocardial infarction. Currently, there is no successful report about hypoxia inducing factor 1 alpha gene transfection of cardiac stem cells, but relevant studies are proceeding. Gene modified cardiac stem cells are expected to be widely used in clinic.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

Key words: Heart, Myocardial Infarction, Hypoxia-Inducible Factor 1, alpha Subunit, Stem Cell Transplantation

CLC Number:

R318

Li Sha, Li Shu-ren, Zhang Qian-hui. Hypoxia inducing factor 1 alpha-transfected cardiac stem cells in repair of necrotic myocardium [J]. Chinese Journal of Tissue Engineering Research, 2015, 19(23): 3750-3754.

Figures/Tables 3

References

[1] 王曼,李树仁.基因工程在骨髓间充质干细胞治疗心肌梗死中的应用[J].中国老年学杂志, 2015,35(1):269-271.

[2] Doppler SA, Deutsch MA, Lange R, et al. Cardiac regeneration: current therapies-future concepts. J Thorac Dis. 2013;5(5):683-697.

[3] Leri A, Kajstura J, Anversa P. Cardiac stem cells and mechanisms of myocardial regeneration. Physiol Rev. 2005; 85(4):1373-1416.

[4] Nam YJ, Song K, Olson EN. Heart repair by cardiac reprogramming.Nat Med. 2013;19(4):413-415.

[5] Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114(6):763-776.

[6] Rota M, Padin-Iruegas ME, Misao Y, et al. Local activation or implantation of cardiac progenitor cells rescues scarred infarcted myocardium improving cardiac function. Circ Res. 2008;103(1):107-116.

[7] Bearzi C, Rota M, Hosoda T, et al. Human cardiac stem cells. Proc Natl Acad Sci U S A. 2007;104(35):14068-14073.

[8] Kuang D, Zhao X, Xiao G, et al. Stem cell factor/c-kit signaling mediated cardiac stem cell migration via activation of p38 MAPK. Basic Res Cardiol. 2008;103(3):265-273.

[9] Wang X, Hu Q, Nakamura Y, et al. The role of the sca-1+/ CD31- cardiac progenitor cell population in postinfarction left ventricular remodeling. Stem Cells. 2006; 24(7):1779-1788.

[10] Matsuura K, Nagai T, Nishigaki N, et al. Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes. J Biol Chem. 2004;279(12):11384-11391.

[11] Mouquet F, Pfister O, Jain M, et al. Restoration of cardiac progenitor cells after myocardial infarction by self-proliferation and selective homing of bone marrow-derived stem cells. Circ Res. 2005;97(11):1090-1092.

[12] Moretti A, Caron L, Nakano A, et al. Multipotent embryonic isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. Cell. 2006;127(6):1151-1165.

[13] D'Amario D, Fiorini C, Campbell PM, et al. Functionally competent cardiac stem cells can be isolated from endomyocardial biopsies of patients with advanced cardiomyopathies. Circ Res. 2011;108(7):857-861.

[14] Matsuura K, Honda A, Nagai T, et al. Transplantation of cardiac progenitor cells ameliorates cardiac dysfunction after myocardial infarction in mice. J Clin Invest. 2009;119(8): 2204-2217.

[15] Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378 (9806):1847-1857.

[16] Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012;379(9819):895-904.

[17] Cai Z, Manalo DJ, Wei G, et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation. 2003;108(1):79-85.

[18] Tal R.The role of hypoxia and hypoxia-inducible factor-1alpha in preeclampsia pathogenesis. Biol Reprod. 2012;87(6):134.

[19] Hinkel R, Lebherz C, Fydanaki M, et al. Angiogenetic potential of Ad2/Hif-1α/VP16 after regional application in a preclinical pig model of chronic ischemia. Curr Vasc Pharmacol. 2013;11(1):29-37.

[20] Zisa D, Shabbir A, Suzuki G, et al. Vascular endothelial growth factor (VEGF) as a key therapeutic trophic factor in bone marrow mesenchymal stem cell-mediated cardiac repair. Biochem Biophys Res Commun. 2009;390(3):834-838.

[21] Xu Y, Zuo Y, Zhang H, et al. Induction of SENP1 in endothelial cells contributes to hypoxia-driven VEGF expression and angiogenesis. J Biol Chem. 2010;285(47):36682-36688.

[22] Ahluwalia A, Tarnawski AS. Critical role of hypoxia sensor--HIF-1α in VEGF gene activation. Implications for angiogenesis and tissue injury healing. Curr Med Chem. 2012; 19(1):90-97.

[23] Semenza GL. Regulation of metabolism by hypoxia-inducible factor 1. Cold Spring Harb Symp Quant Biol. 2011;76: 347-353.

[24] Mergenthaler P, Kahl A, Kamitz A, et al. Mitochondrial hexokinase II (HKII) and phosphoprotein enriched in astrocytes (PEA15) form a molecular switch governing cellular fate depending on the metabolic state. Proc Natl Acad Sci U S A. 2012;109(5):1518-1523.

[25] Le Moine CM, Morash AJ, McClelland GB. Changes in HIF-1α protein, pyruvate dehydrogenase phosphorylation, and activity with exercise in acute and chronic hypoxia. Am J Physiol Regul Integr Comp Physiol. 2011;301(4):R1098-1104.

[26] 周启璠,于淼,陈国良,等. 缺氧诱导因子-1及其抑制剂的研究进展[J]. 中国药物化学杂志,2014,24(1):48-58.

[27] Chu W, Li X, Li C, et al. TGFBR3, a potential negative regulator of TGF-β signaling, protects cardiac fibroblasts from hypoxia-induced apoptosis. J Cell Physiol. 2011;226(10): 2586-2594.

[28] Zhang Q, Qian Z, Pan L, et al. Hypoxia-inducible factor 1 mediates the anti-apoptosis of berberine in neurons during hypoxia/ischemia. Acta Physiol Hung. 2012;99(3):311-323.

[29] Yang B, He K, Zheng F, et al. Over-expression of hypoxia-inducible factor-1 alpha in vitro protects the cardiac fibroblasts from hypoxia-induced apoptosis. J Cardiovasc Med (Hagerstown). 2014;15(7):579-586.

[30] Park JS, Na K, Woo DG, et al. Non-viral gene delivery of DNA polyplexed with nanoparticles transfected into human mesenchymal stem cells. Biomaterials. 2010;31(1):124-132.

[31] Saridey SK, Liu L, Doherty JE, et al. PiggyBac transposon-based inducible gene expression in vivo after somatic cell gene transfer. Mol Ther. 2009;17(12):2115-2120.

[32] Woltjen K, Michael IP, Mohseni P, et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature. 2009;458(7239):766-770.

[33] Campbell NG, Suzuki K. Cell delivery routes for stem cell therapy to the heart: current and future approaches. J Cardiovasc Transl Res. 2012;5(5):713-726.

[34] Dib N, Khawaja H, Varner S, et al. Cell therapy for cardiovascular disease: a comparison of methods of delivery. J Cardiovasc Transl Res. 2011;4(2):177-181.

[35] Krenn L, Kopp C, Glogar D, et al. Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents in patients with multivessel coronary artery disease compared to coronary artery bypass surgery five-years after intervention. Catheter Cardiovasc Interv. 2014;84(7):1029-1039.

[36] Tuma J, Fernández-Viña R, Carrasco A, et al. Safety and feasibility of percutaneous retrograde coronary sinus delivery of autologous bone marrow mononuclear cell transplantation in patients with chronic refractory angina. J Transl Med. 2011;9:183.

[37] Fujimoto KL, Tobita K, Guan J, et al. Placement of an elastic biodegradable cardiac patch on a subacute infarcted heart leads to cellularization with early developmental cardiomyocyte characteristics. J Card Fail. 2012;18(7):585- 595.